The first phase 2 study will enroll about 100 liver cancer patients who had no prior treatment, the company said. It will test the ability of SRF388 in improving progression-free survival when combined with Roche's atezolizumab and bevacizumab. Final data are expected in the first half of 2024.
The second phase 2 trial is enrolling up to 40 non-small-cell lung cancer patients who had at least one round of treatment to test SRF388 as a standalone therapy. The primary endpoint will be overall response rate, with data readout expected next year.
The drugmaker's shares were up 4.6% in recent early premarket activity Thursday.
Price: 2.75, Change: +0.12, Percent Change: +4.56
|Otis Worldwide Names Anurag Maheshwari as CFO|
|Global Surplus Crude Oil Production Capacity Plunges...|
|US Housing Market Slowdown to Weigh on Pace of Fed's...|
|Asian Stock Markets Track Higher On Pandemic, Recess...|
|Wedbush Cuts PT on Xenon Pharmaceuticals to $41 From...|